Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

NCT03361319 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawal of financial support from funder

Conditions

NSCLC, Recurrent
Adenocarcinoma of Lung

Interventions

DRUG: Vargatef
DRUG: Abraxane
OTHER: placebo

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

[object Object]
[object Object]